Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376318 | 1.00 | MEN1 (0.37) | MEN1CYP2C9KMT2ASIGMAR1ADRA2A | |
| SCHEMBL29190477 | 0.81 | TMEM97 (0.41) | SIGMAR1ADRA2A | |
| SCHEMBL12622887 | 0.80 | TMEM97 (0.40) | CYP2C9SIGMAR1ADRA2AOPRM1OPRK1 | |
| SCHEMBL2360287 | 0.79 | SIGMAR1 (0.52) | SIGMAR1ADRA2AOPRM1OPRD1 | |
| SCHEMBL3406036 | 0.79 | SIGMAR1 (0.37) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 | |
| SCHEMBL736557 | 0.79 | SIGMAR1 (0.52) | SIGMAR1ADRA2AOPRM1OPRD1 | |
| SCHEMBL11334162 | 0.78 | OPRD1 (0.49) | MEN1CYP2C9KMT2ASIGMAR1OPRM1 | |
| SCHEMBL11334163 | 0.78 | OPRD1 (0.49) | MEN1CYP2C9KMT2ASIGMAR1OPRM1 | |
| SCHEMBL26011230 | 0.77 | SIGMAR1 (0.42) | SIGMAR1ADRA2A | |
| SCHEMBL11864088 | 0.77 | SIGMAR1 (0.54) | SIGMAR1ADRA2AOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| CN-116261557-A | Cyclic cyanoketene derivatives as KEAP1 modulators | 默沙东有限责任公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2022013408-A2 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | MEN1 3912/4885CYP2C9 1874/4885KMT2A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.